Kanāda - angļu - Health Canada

icu medical canada inc - l-threonine; tryptophan; l-valine; l-lysine (lysine acetate); methionine; l-phenylalanine; l-alanine; l-arginine; l-aspartic acid; glutamic acid; glycine; histidine; l-proline; serine; n-acetyl-l-tyrosine; l-isoleucine; l-leucine - solution - 600mg; 300mg; 750mg; 1575mg; 258mg; 447mg; 1490mg; 1527mg; 1050mg; 1107mg; 750mg; 450mg; 1083mg; 795mg; 405mg; 990mg; 1500mg - l-threonine 600mg; tryptophan 300mg; l-valine 750mg; l-lysine (lysine acetate) 1575mg; methionine 258mg; l-phenylalanine 447mg; l-alanine 1490mg; l-arginine 1527mg; l-aspartic acid 1050mg; glutamic acid 1107mg; glycine 750mg; histidine 450mg; l-proline 1083mg; serine 795mg; n-acetyl-l-tyrosine 405mg; l-isoleucine 990mg; l-leucine 1500mg - caloric agents

Kanāda - angļu - Health Canada

warner chilcott canada co - risedronate sodium; calcium (calcium carbonate) - tablet - 35mg; 500mg - risedronate sodium 35mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors

Kanāda - angļu - Health Canada

sanis health inc - risedronate sodium (risedronate sodium monohydrate) - tablet - 5mg - risedronate sodium (risedronate sodium monohydrate) 5mg - bone resorption inhibitors

Kanāda - angļu - Health Canada

sanis health inc - risedronate sodium (risedronate sodium monohydrate) - tablet - 30mg - risedronate sodium (risedronate sodium monohydrate) 30mg - bone resorption inhibitors

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

actavis pharma, inc. - ethynodiol diacetate (unii: 62h10a1236) (ethynodiol - unii:9e01c36a9s) - ethynodiol diacetate 1 mg

Kanāda - angļu - Health Canada

pharmel inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - lamivudine tablet is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-l) infection. limitations of use: • the dosage of this product is for hiv-1 and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data ). the apr uses the macdp as the u.s. reference population for birth defects in the general popu

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

warner chilcott (us), llc - mesalamine (unii: 4q81i59gxc) (mesalamine - unii:4q81i59gxc) - mesalamine 400 mg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

actavis pharma, inc. - estropipate (unii: svi38uy019) (estrone - unii:2di9ha706a) - estropipate 1.5 mg - estropipate tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for

Kanāda - angļu - Health Canada

sanis health inc - etidronate disodium; calcium (calcium carbonate) - tablet - 400mg; 500mg - etidronate disodium 400mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors